John McCamant

We are recommending Celldex Therapeutics Inc. (CLDX) as a more conservative biotech Top Pick for 2026. CLDX has just initiated the second Phase III/registration study with its lead compound barzolvolimab (“barzo”) in chronic inducible urticaria (CIndU), observes John McCamant, editor of Medical Technology Stock Letter.

We are recommending Wave Life Sciences Ltd. (WVE) as our more aggressive biotech Top Pick for 2026. The company is an emerging leader in discovery and drug development based on their pioneering best-in-class RNA chemistry, advises John McCamant, editor of Medical Technology Stock Letter.

Pfizer Inc. (PFE) finally topped Novo Nordisk (NVO) to buy Metsera after Novo raised its bid twice. Metsera’s crown jewel is MET-097i, a weekly and monthly injectable GLP-1 asset that’s about to begin Phase III development, writes John McCamant, editor of Medical Technology Stock Letter. Pfizer ended up paying $10 billion, a significant uptick from the $5 billion value of the companies’ original buyout deal, inked in September.